|
1
|
Delattre O, Zucman J, Plougastel B, et al:
Gene fusion with an ETS DNA-binding domain caused by chromosome
translocation in human tumours. Nature. 359:162–165. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lahl M, Fisher VL and Laschinger K:
Ewing’s sarcoma family of tumors: an overview from diagnosis to
survivorship. Clin J Oncol Nurs. 12:89–97. 2008.
|
|
3
|
Balamuth NJ and Womer RB: Ewing’s sarcoma.
Lancet Oncol. 11:184–192. 2010.
|
|
4
|
Linabery AM and Ross JA: Trends in
childhood cancer incidence in the U.S. (1992–2004). Cancer.
112:416–432. 2008.
|
|
5
|
May WA, Lessnick SL, Braun BS, et al: The
Ewing’s sarcoma EWS/FLI-1 fusion gene encodes a more potent
transcriptional activator and is a more powerful transforming gene
than FLI-1. Mol Cell Biol. 13:7393–7398. 1993.
|
|
6
|
Prieur A, Tirode F, Cohen P and Delattre
O: EWS/FLI-1 silencing and gene profiling of Ewing cells reveal
downstream oncogenic pathways and a crucial role for repression of
insulin-like growth factor binding protein 3. Mol Cell Biol.
24:7275–7283. 2004. View Article : Google Scholar
|
|
7
|
Toomey EC, Schiffman JD and Lessnick SL:
Recent advances in the molecular pathogenesis of Ewing’s sarcoma.
Oncogene. 29:4504–4516. 2010.
|
|
8
|
Erkizan HV, Uversky VN and Toretsky JA:
Oncogenic partnerships: EWS-FLI1 protein interactions initiate key
pathways of Ewing’s sarcoma. Clin Cancer Res. 16:4077–4083.
2010.PubMed/NCBI
|
|
9
|
Kovar H: Downstream EWS/FLI1-upstream
Ewing’s sarcoma. Genome Med. 2:82010.PubMed/NCBI
|
|
10
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar
|
|
11
|
Malumbres M and Barbacid M: To cycle or
not to cycle: a critical decision in cancer. Nat Rev Cancer.
1:222–231. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kowalewski AA, Randall RL and Lessnick SL:
Cell cycle deregulation in Ewing’s sarcoma pathogenesis. Sarcoma.
2011:5987042011.
|
|
13
|
Kauer M, Ban J, Kofler R, Walker B, Davis
S, Meltzer P and Kovar H: A molecular function map of Ewing’s
sarcoma. PLoS One. 4:e54152009.
|
|
14
|
Katoh M, Igarashi M, Fukuda H, Nakagama H
and Katoh M: Cancer genetics and genomics of human FOX family
genes. Cancer Lett. 328:198–206. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Myatt SS and Lam EW: The emerging roles of
forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 7:847–859.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kinsey M, Smith R and Lessnick SL: NR0B1
is required for the oncogenic phenotype mediated by EWS/FLI in
Ewing’s sarcoma. Mol Cancer Res. 4:851–859. 2006.
|
|
17
|
Laoukili J, Kooistra MR, Brás A, et al:
FoxM1 is required for execution of the mitotic programme and
chromosome stability. Nat Cell Biol. 7:126–136. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wierstra I and Alves J: FOXM1, a typical
proliferation-associated transcription factor. Biol Chem.
388:1257–1274. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kalinichenko VV, Major ML, Wang X, et al:
Foxm1b transcription factor is essential for development of
hepatocellular carcinomas and is negatively regulated by the p19ARF
tumor suppressor. Genes Dev. 18:830–850. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kalin TV, Wang IC, Ackerson TJ, et al:
Increased levels of the FoxM1 transcription factor accelerate
development and progression of prostate carcinomas in both TRAMP
and LADY transgenic mice. Cancer Res. 66:1712–1720. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim IM, Ackerson T, Ramakrishna S, et al:
The Forkhead Box m1 transcription factor stimulates the
proliferation of tumor cells during development of lung cancer.
Cancer Res. 66:2153–2161. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu M, Dai B, Kang SH, et al: FoxM1B is
overexpressed in human glioblastomas and critically regulates the
tumorigenicity of glioma cells. Cancer Res. 66:3593–3602. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Z, Banerjee S, Kong D, Li Y and
Sarkar FH: Down-regulation of Forkhead Box M1 transcription factor
leads to the inhibition of invasion and angiogenesis of pancreatic
cancer cells. Cancer Res. 67:8293–8300. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chan DW, Yu SY, Chiu PM, Yao KM, Liu VW,
Cheung AN and Ngan HY: Over-expression of FOXM1 transcription
factor is associated with cervical cancer progression and
pathogenesis. J Pathol. 215:245–252. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Francis RE, Myatt SS, Krol J, et al: FoxM1
is a downstream target and marker of HER2 overexpression in breast
cancer. Int J Oncol. 35:57–68. 2009.PubMed/NCBI
|
|
26
|
Laoukili J, Stahl M and Medema RH: FoxM1:
at the crossroads of ageing and cancer. Biochim Biophys Acta.
1775:92–102. 2007.PubMed/NCBI
|
|
27
|
Gemenetzidis E, Bose A, Riaz AM, et al:
FOXM1 upregulation is an early event in human squamous cell
carcinoma and it is enhanced by nicotine during malignant
transformation. PLoS One. 4:e48492009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hegde NS, Sanders DA, Rodriguez R and
Balasubramanian S: The transcription factor FOXM1 is a cellular
target of the natural product thiostrepton. Nat Chem. 3:725–731.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kwok JM, Myatt SS, Marson CM, Coombes RC,
Constantinidou D and Lam EW: Thiostrepton selectively targets
breast cancer cells through inhibition of forkhead box M1
expression. Mol Cancer Ther. 7:2022–2032. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Christensen L, Joo J, Lee S, Wai D, Triche
TJ and May WA: FOXM1 is an oncogenic mediator in Ewing sarcoma.
PLoS One. 8:e545562013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mateo-Lozano S, Gokhale PC, Soldatenkov
VA, Dritschilo A, Tirado OM and Notario V: Combined transcriptional
and translational targeting of EWS/FLI-1 in Ewing’s sarcoma. Clin
Cancer Res. 12:6781–6790. 2006.PubMed/NCBI
|
|
32
|
Tirado OM, Mateo-Lozano S and Notario V:
Roscovitine is an effective inducer of apoptosis of Ewing’s sarcoma
family tumor cells in vitro and in vivo. Cancer Res. 65:9320–9327.
2005.PubMed/NCBI
|
|
33
|
Kinsey M, Smith R, Iyer AK, McCabe ER and
Lessnick SL: EWS/FLI and its downstream target NR0B1 interact
directly to modulate transcription and oncogenesis in Ewing’s
sarcoma. Cancer Res. 69:9047–9055. 2009.PubMed/NCBI
|
|
34
|
Korver W, Roose J and Clevers H: The
winged-helix transcription factor Trident is expressed in cycling
cells. Nucleic Acids Res. 25:1715–1719. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang IC, Chen YJ, Hughes D, et al:
Forkhead box M1 regulates the transcriptional network of genes
essential for mitotic progression and genes encoding the SCF
(Skp2-Cks1) ubiquitin ligase. Mol Cell Biol. 25:10875–10894. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Halasi M and Gartel AL: FOX(M1) news - it
is cancer. Mol Cancer Ther. 12:245–254. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nicolaou KC, Zak M, Rahimipour S, et al:
Discovery of a biologically active thiostrepton fragment. J Am Chem
Soc. 127:15042–15044. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bhat UG, Halasi M and Gartel AL: Thiazole
antibiotics target FoxM1 and induce apoptosis in human cancer
cells. PLoS One. 4:e55922009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Schoof S, Pradel G, Aminake MN, et al:
Antiplasmodial thiostrepton derivatives: proteasome inhibitors with
a dual mode of action. Angew Chem Int. 49:3317–3321. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
White SR, Williams P, Wojcik KR, Sun S,
Hiemstra PS, Rabe KF and Dorscheid DR: Initiation of apoptosis by
actin cytoskeletal derangement in human airway epithelial cells. Am
J Respir Cell Mol Biol. 24:282–294. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dai B, Kang SH, Gong W, Liu M, Aldape KD,
Sawaya R and Huang S: Aberrant FoxM1B expression increases matrix
metalloproteinase-2 transcription and enhances the invasion of
glioma cells. Oncogene. 26:6212–6219. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Littler DR, Alvarez-Fernández M, Stein A,
et al: Structure of the FoxM1 DNA-recognition domain bound to a
promoter sequence. Nucleic Acids Res. 38:4527–4538. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Pandit B and Gartel AL: New potential
anti-cancer agents synergize with bortezomib and ABT-737 against
prostate cancer. Prostate. 70:825–833. 2010.PubMed/NCBI
|
|
44
|
Wang M and Gartel AL: Micelle-encapsulated
thiostrepton as an effective nanomedicine for inhibiting tumor
growth and for suppressing FOXM1 in human xenografts. Mol Cancer
Ther. 10:2287–2297. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pandit B and Gartel AL: FoxM1 knockdown
sensitizes human cancer cells to proteasome inhibitor-induced
apoptosis but not to autophagy. Cell Cycle. 10:3269–3273. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Uddin S, Hussain AR, Ahmed M, Siddiqui K,
Al-Dayel F, Bavi P and Al-Kuraya KS: Overexpression of FoxM1 offers
a promising therapeutic target in diffuse large B-cell lymphoma.
Haematologica. 97:1092–1100. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Radhakrishnan SK and Gartel AL: FOXM1: the
Achilles’ heel of cancer? Nat Rev Cancer. 8:c12008.PubMed/NCBI
|
|
48
|
Chan DW, Hui WW, Cai PC, et al: Targeting
GRB7/ERK/FOXM1 signaling pathway impairs aggressiveness of ovarian
cancer cells. PLoS One. 7:e525782012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang Y, Wen L, Zhao SH, Ai ZH, Guo JZ and
Liu WC: FoxM1 expression is significantly associated with
cisplatin-based chemotherapy resistance and poor prognosis in
advanced non-small cell lung cancer patients. Lung Cancer.
79:173–179. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Mateo-Lozano S, Tirado OM and Notario V:
Rapamycin induces the fusion-type independent downregulation of the
EWS/FLI-1 proteins and inhibits Ewing’s sarcoma cell proliferation.
Oncogene. 22:9282–9287. 2003.PubMed/NCBI
|
